Molecular mechanism of tumor associated hypercoagulability

Abstract

Zhang Xue, Jiang Da, Li Ying. Molecular mechanism of tumor associated hypercoagulability[J]. Journal of International Oncology, 2016, 43(5): 356-359.

［1］赵晶, 姜达. 恶性肿瘤高凝状态及其干预［J］. 癌症进展, 2013, 11(1): 48-52. ［2］陈国荣. 恶性肿瘤患者血栓的形成机制与诊断进展［J］. 新乡医学院学报, 2015, 32(9): 891-893. ［3］ Anand M, Brat DJ. Oncogenic regulation of tissue factor and thrombosis in cancer［J］. Thromb Res, 2012, 129 Suppl 1: S46-S49. DOI: 10.1016/S00493848(12)700154. ［4］付晓飞, 杨之斌, 殷正丰. 血小板与循环肿瘤细胞［J］. 肿瘤, 2014, 34(3): 286-290. ［5］ Grane CA, Han SJ, Barry JJ, et al. TGFbeta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients［J］. Neuro Oncol, 2010, 12(1): 7-13. DOI: 10.1093/neuonc/nop009. ［6］ Gigante M, Gesualdo L, Ranieri E.TGFbeta: a master switch in tumor immunity［J］. Curr Pharm Des, 2012, 18(27): 4126-4134. ［7］ Van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside［J］. Blood, 2012, 119(4): 924-932. DOI: 10.1182/blood201106317685. ［8］ Godby RC, van den Berg YW, Srinvasan RS, et al. Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrinmediated signaling in murine models［J］. Mol Med, 2012, 18(1): 771-779. DOI: 10.2119/molmed.2011.00416. ［9］ Srinivasan R, Ozhegov E, van den Berg YW, et al. Splice variants of tissue factor promote monocyteendothelial interactions by triggering the expression of cell adhesion molecules via integrinmediated signaling［J］. Thromb Haemost, 2011, 9(10): 2087-2096. DOI: 10.1111/j.15387836.2011.04454. ［10］ Ettelaie C, Collier ME, Mei MP, et al. Enhanced binding of tissue factor microparticles to collagenⅣ and fibronectin leads to increased tissue factor activity in vitro［J］. Thromb Haemost, 2013, 109(1): 61-71. DOI: 10.1160/TH12050279. ［11］ Magnus N, Garnier D, Meehan B, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations［J］. Proc Natl Acad Sci USA, 2014, 111(9): 3544-3549. ［12］ Breij EC, de Goeij BE, Verploegen S, et al. An antibodydrug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors［J］. Caner Res, 2014, 74(4): 1214-1226. DOI: 10.1158/00085472.CAN132440. ［13］ Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosomelike extracellular vesicles carrying tissue factor［J］. J Biol Chem， 2012, 287(52): 43565-43572. DOI: 10.1074/jbc.M112. 401760. ［14］ Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissuefactorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation［J］. Blood, 2005, 106(5): 1604-1611. ［15］ Hathcock J, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Ⅹa［J］. Blood, 2004, 104(1):123-127. ［16］ Zwicker JI, Liebman H, Neuberg D, et al. Tumorderived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy［J］. Clin Cancer Res, 2009, 15(22): 6830-6840. DOI: 10.1158/10780432. CCR090371. ［17］ Nadir Y, Brenner B. Heparanase multiple effects in cancer［J］. Thromb Res, 2014, 133Suppl 2: S90-S94. DOI: 10.1016/S00493848(14)500151. ［18］ Menschikowski M, Hagelgans A, Tiebel O, et al. Regulation of thrombomodulin expression in prostate cancer cells［J］. Cancer Lett, 2012, 322(2): 177-184. DOI: 10.1016/j.canlet.2012.03.001. ［19］ Chen LM, Wang W, Lee JC, et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells［J］. Tumour Biol, 2013, 34(6): 3743-3751. DOI: 10.1007/s132770130958x. ［20］ Demers M, Wagner DD. Neutrophil extracellular traps: A new link to cancerassociated thrombosis and potential implications for tumor progression［J］. Oncol Immunol, 2013, 2(2): e22946. ［21］ Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancerassociated thrombosis［J］. Proc Natl Acad Sci USA, 2012, 109(32): 13076-13081. DOI: 10.1073/pnas.1200419109. ［22］ Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases［J］. Nat Med， 2010, 16(8): 887-896. DOI: 10.1038/nm.2184. ［23］ Buck K, Hug S, Seibold P, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk［J］. Breast Cancer Res Treat, 2013, 137(3): 927-937. DOI: 10.1007/s1054901223259. ［24］ Bretz NP, Salnikov AV, Perne C, et al. CD24 controls Src/STAT3 activity in human tumors［J］. Cell Mol Life Sci, 2012, 69(22): 3863-3879. DOI: 10.1007/s0001801210559. ［25］ Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype［J］. Biochem Biophys Res Commun, 2013, 432(2): 333-338. DOI: 10.1016/j.bbrc.2013.01.102. ［26］ Rao B, Gao Y, Huang J, et al. Mutations of p53 and Kras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis［J］. Int J Colorectal Dis, 2011, 26(5): 593-601. DOI: 10.1007/s00384 01111641. ［27］ Yu JL, Xing R, Milsom C, et al. Modulation of the oncogenedependent tissue factor expression by kinase suppressor of ras1［J］. Thromb Res, 2010, 126(1): e6-e10. DOI: 10.1016/j.thromres.2010.04.014.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Molecular mechanism of tumor associated hypercoagulability

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments